Latest & greatest articles for Skin Ulcer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Skin Ulcer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Skin Ulcer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Skin Ulcer

1. Interventions for ulceration and other skin changes caused by nerve damage in leprosy. (Abstract)

Interventions for ulceration and other skin changes caused by nerve damage in leprosy. At the end of 2016, 145 countries reported to the World Health Organization (WHO) over 173,000 new cases of leprosy worldwide. In the past 20 years, over 16 million people have been treated for leprosy globally. The condition's main complications are injuries and ulceration caused by sensory loss from nerve damage. In this review we explored interventions to prevent or treat secondary damage to the skin (...) existing ulcers, one of them also evaluated prevention of new ulcers. One study aimed to prevent skin changes, such as cracking and fissures. Investigated interventions included: laser therapy, light-emitting diode (LED), zinc tape, intralesional pentoxifylline, pulsed magnetic fields, wax therapy, ketanserin, human amniotic membrane gel, phenytoin, plaster shoes, and footwear.We are uncertain about the following key results, as the certainty of evidence is very low. All time points were measured from

2019 Cochrane

2. Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis

Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how (...) have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies. Ulcerative colitis Hyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant

2018 European Medicines Agency - EPARs

3. Palliative care - malignant skin ulcer

Palliative care - malignant skin ulcer Palliative care - malignant skin ulcer - NICE CKS Share Palliative care - malignant skin ulcer: Summary A malignant ulcer is a proliferative or cavitating primary or secondary cancer in the skin. It may appear as a crater-like wound, a nodular 'fungus', or a 'cauliflower' lesion. Most malignant ulcers develop from a breast, head and neck, or skin cancer. Malignant ulcers are most likely to develop in people older than 70 years of age with metastatic cancer (...) and a life expectancy of 6 months or less. Primary care management of a malignant skin ulcer includes: Assessment of the malignant skin ulcer including the type, site and size of the ulcer, the presence of necrotic tissue, condition of the surrounding skin, and the presence of complications. Discussing with the person their concerns, treatment priorities, and advising that healing is unlikely to be a realistic goal, but that the aim is to maintain the person’s quality of life as much as possible

2018 NICE Clinical Knowledge Summaries

4. Genital Skin Lesions (Non-Ulcerative)

Genital Skin Lesions (Non-Ulcerative) MANAGEMENT SUMMARY Genital Skin Lesions (Non-Ulcerative) Patient complains of genital skin lump(s) / bump(s) Examination Note the appearance and location of lesions – together with the history, this is usually sufficient to make a diagnosis. Discrete lumps or bumps in the genital region may be due to normal anatomical findings, or may be due to a small number of sexually transmissible infections. Unusual lesions, including pigmented lesions, should (...) be referred for a specialist opinion before any treatment occurs. Normal anatomical variants Males • Pearly penile papules (coronal papillae), Fordyce glands. Females • Vestibular papillomatosis, Fordyce glands Genital warts Exophytic skin lesions that vary in size/shape and number. Males • Typically at leading edge of prepuce, on frenulum, or more sporadically in coronal sulcus, on penile shaft. Less frequently on scrotum or in pubic area or perianal. Females • Usually vulval (often posteriorly

2017 New Zealand Sexual Health Society

5. Comparative effectiveness of skin substitutes for chronic venous leg ulcers in adults: a review of reviews

Comparative effectiveness of skin substitutes for chronic venous leg ulcers in adults: a review of reviews Comparative effectiveness of skin substitutes for chronic venous leg ulcers in adults: a review of reviews Comparative effectiveness of skin substitutes for chronic venous leg ulcers in adults: a review of reviews HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation HAYES, Inc. Comparative effectiveness of skin substitutes for chronic venous leg ulcers in adults: a review of reviews. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Health Problem: Venous leg ulcers, also known as venous stasis ulcers or varicose ulcers, are partial or full-thickness defects in the skin of the lower leg, typically between the knee and the ankle, caused by venous hypertension as a result of valvular incompetence and venous reflux

2017 Health Technology Assessment (HTA) Database.

6. Comparative effectiveness of skin substitutes for chronic foot ulcers in adults with diabetes mellitus: a review of reviews

Comparative effectiveness of skin substitutes for chronic foot ulcers in adults with diabetes mellitus: a review of reviews Comparative effectiveness of skin substitutes for chronic foot ulcers in adults with diabetes mellitus: a review of reviews Comparative effectiveness of skin substitutes for chronic foot ulcers in adults with diabetes mellitus: a review of reviews HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Comparative effectiveness of skin substitutes for chronic foot ulcers in adults with diabetes mellitus: a review of reviews. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Health Problem: Diabetes can damage blood vessels, compromising blood flow and oxygen circulation. Resulting tissue hypoxia may contribute to failure of even minor wounds to heal. Reasons are multifactorial and may include

2017 Health Technology Assessment (HTA) Database.

7. Prevention of Pressure Ulcers and Skin Degradation in Wheelchair Users: Guidelines

Prevention of Pressure Ulcers and Skin Degradation in Wheelchair Users: Guidelines Prevention of Pressure Ulcers and Skin Degradation in Wheelchair Users: Guidelines | CADTH.ca Find the information you need Prevention of Pressure Ulcers and Skin Degradation in Wheelchair Users: Guidelines Prevention of Pressure Ulcers and Skin Degradation in Wheelchair Users: Guidelines Published on: October 7, 2015 Project Number: RA0810-000 Product Line: Research Type: Devices and Systems Report Type (...) : Reference List Result type: Report Question What are the evidence-based guidelines regarding the management of heat and moisture in seating systems of wheelchair bound individuals? Key Message One evidence-based guideline regarding the management of heat and moisture for pressure ulcer prevention for wheelchair bound individuals was identified. Tags hot temperature, pressure ulcer, skin ulcer, wheelchairs, wounds and injuries, other miscellaneous topics, automated chair, cushion, decubitis, decubitus

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study (Abstract)

Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study Introduction The early detection of systemic sclerosis (SSc) patients at high risk of developing digital ulcers could allow preventive treatment, with a reduction of morbidity and social costs. In 2009, a quantitative score, the capillaroscopic skin ulcer risk index (CSURI), calculated according to the formula 'D×M/N(2'), was proposed, which was highly predictive of the appearance (...) of scleroderma digital ulcers within 3 months of capillaroscopic evaluation.This multicentre study aims to validate the predictive value and reproducibility of CSURI in a large population of SSc patients.CSURI was analysed in 229 unselected SSc patients by nailfold videocapillaroscopy (NVC). All patients were re-evaluated 3 months later with regard to the persistence and/or appearance of new digital ulcers.57 of 229 patients presented with digital ulcers after 3 months. The receiver operating characteristic

2012 EvidenceUpdates

9. Randomised controlled trial: Skin protection wheelchair cushions for older nursing home residents reduce 6-month incidence of ischial tuberosity pressure ulcers compared with segmented foam cushions

Randomised controlled trial: Skin protection wheelchair cushions for older nursing home residents reduce 6-month incidence of ischial tuberosity pressure ulcers compared with segmented foam cushions Skin protection wheelchair cushions for older nursing home residents reduce 6-month incidence of ischial tuberosity pressure ulcers compared with segmented foam cushions | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage (...) wheelchair cushions for older nursing home residents reduce 6-month incidence of ischial tuberosity pressure ulcers compared with segmented foam cushions Article Text Care of the older person Randomised controlled trial Skin protection wheelchair cushions for older nursing home residents reduce 6-month incidence of ischial tuberosity pressure ulcers compared with segmented foam cushions Dimitri Beeckman 1 , 2 , Katrien Vanderwee 2 Statistics from Altmetric.com Commentary on: Brienza D , Kelsey S , Karg P

2011 Evidence-Based Nursing

10. The evidence for the use of growth factors and active skin substitutes for the treatment of non-infected diabetic foot ulcers (DFU): a health technology assessment (HTA)

The evidence for the use of growth factors and active skin substitutes for the treatment of non-infected diabetic foot ulcers (DFU): a health technology assessment (HTA) The evidence for the use of growth factors and active skin substitutes for the treatment of non-infected diabetic foot ulcers (DFU): a health technology assessment (HTA) The evidence for the use of growth factors and active skin substitutes for the treatment of non-infected diabetic foot ulcers (DFU): a health technology (...) assessment (HTA) Buchberger B, Follmann M, Freyer D, Huppertz H, Ehm A, Wasem J CRD summary This review concluded that add-on therapy with growth factors or active skin substitutes could be an alternative to standard wound care alone for treatment of diabetic foot ulcers, but their use could not be explicitly recommended without stronger evidence. These conclusions appropriately reflect the limitations of the evidence presented. Authors' objectives To assess the safety and effectiveness of growth factors

2011 DARE.

11. Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes Full Text available with Trip Pro

Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes Barber C, Watt A, Pham C, Humphreys K, Penington A, Mutimer K, Edwards M, Maddern G CRD summary This review evaluated the safety and effectiveness of bioengineered skin substitutes compared with standard (...) dressings and/or autografts when used on chronic wounds. It found that bioengineered skin substitutes (with a dermal component) may improve healing outcomes in diabetic foot ulcers and venous leg ulcers. Lack of reporting of statistical tests means the reliability of the authors' conclusions is unclear. Authors' objectives To evaluate the safety and effectiveness of bioengineered skin substitutes compared with standard dressings and/or standard autografts when used on chronic wounds. Searching MEDLINE

2008 DARE.

12. Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert)

Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert) Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert) Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert) Swedish Council on Technology Assessment in Health Care Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Swedish Council on Technology Assessment in Health Care. Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert) Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 2003 Authors' objectives This review aims to assess the available evidence on transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers. Authors

2003 Health Technology Assessment (HTA) Database.

13. Transplantation of cultured skin (Apligraf®) in treating venous leg ulcers</a>

Transplantation of cultured skin (Apligraf®) in treating venous leg ulcers Transplantation of cultured skin (Apligraf®) in treating venous leg ulcers We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Transplantation of cultured skin (Apligraf®) in treating venous leg ulcers Share: Reading time approx. 7 minutes This document was published more (...) . The dominating therapy is compression treatment. Transplantation of the patients own tissue (autologous transplantation) is used to treat hard-to-heal ulcers, but new methods involving cultured skin have been developed that utilize other human tissue. A major advantage of this method, compared to autologous transplantation, is sparing the patient from treatment demanding skin defects secondary to graft skin harvesting. Apligraf® is one type of cultured human skin equivalent. This material is cultured from

2003 Swedish Council on Technology Assessement

14. Skin ulcers misdiagnosed as pyoderma gangrenosum. (Abstract)

Skin ulcers misdiagnosed as pyoderma gangrenosum. Pyoderma gangrenosum is a diagnosis of exclusion, and the misdiagnosis of pyoderma gangrenosum can result in substantial complications in patients who have other causes of severe cutaneous ulceration.We reviewed the charts of 240 patients with a diagnosis of pyoderma gangrenosum who were evaluated at our institution from 1975 through 2000, including 157 consecutive patients treated for presumed pyoderma gangrenosum from 1984 through 1992. We (...) also reviewed the English-language literature.Ninety-five patients (49 from our institution and 46 described in the literature) had skin ulcers with a clinical resemblance to pyoderma gangrenosum. The final diagnoses were vascular occlusive or venous disease, vasculitis, cancer, primary infection, drug-induced or exogenous tissue injury, and other inflammatory disorders. Of the 95 patients studied, 64 had been treated for pyoderma gangrenosum for a median of 10 months (range, 3 to 180). These 64

2002 NEJM

15. A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers

A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers Steinberg J, Beusterien K, Plante K, Nordin J, Chaikoff E, Arcona S, Kim J, Belletti D A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of living skin equivalent (LSE) to treat diabetic foot ulcers (DFUs). LSE is a bioengineered tissue consisting of dermal and epidermal layers containing human keratocytes and fibroblasts. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients

2002 NHS Economic Evaluation Database.

16. Graftskin for the treatment of skin ulcers

Graftskin for the treatment of skin ulcers Graftskin for the treatment of skin ulcers Graftskin for the treatment of skin ulcers BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please (...) use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Graftskin for the treatment of skin ulcers. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 16(12). 2001 Authors' objectives This Assessment reviews the available evidence to determine whether the use of graftskin in conjunction with good wound care improves health outcomes for patients with skin ulcers, as compared to usual care alone. Project page URL Indexing Status Subject indexing assigned

2001 Health Technology Assessment (HTA) Database.

17. Skin grafting for venous leg ulcers. (Abstract)

Skin grafting for venous leg ulcers. Venous leg ulceration is a common, recurring, disabling condition affecting up to 1% of adults. Treatment is aimed at healing with simple dressings and compression bandages / stockings. Unfortunately in some cases this treatment is unsuccessful with ulcers remaining open for months or years. In order to stimulate healing, some clinicians use skin grafts. These skin grafts may be taken from the patients own uninjured skin (e.g. thigh), may be grown from (...) and conference proceedings, and contacted experts in the field.Randomised controlled trials evaluating skin grafts in the treatment of venous leg ulcers. There was no restriction on articles based on language or publication status.Data extraction and assessment of study quality was undertaken by two reviewers independently. Trials with similar patients, comparisons, and outcomes were pooled.Seven RCTs of skin grafts for venous leg ulcers were identified. In 6 trials patients also received compression

2000 Cochrane

18. Management of skin tears and stage II skin ulcers with two topical regimens: a study of cost minimization

Management of skin tears and stage II skin ulcers with two topical regimens: a study of cost minimization Management of skin tears and stage II skin ulcers with two topical regimens: a study of cost minimization Management of skin tears and stage II skin ulcers with two topical regimens: a study of cost minimization Villasin J V, Vinson J A, Igoe M B, Hendricks L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) size. Thirty-six patients with 76 wounds were included in the study analysis. The intervention group included 22 patients who accounted for 57 wounds in total. The comparator had 14 patients with a total of 19 wounds. Patients with sustained skin tears or stage II ulcers within 24 hours were evaluated during daily rounds by the primary investigator (who also administered the treatment) and by the head nurse of the relevant ward. Study design The study was a randomised controlled clinical trial

1996 NHS Economic Evaluation Database.

19. A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers

A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers Margolis D J, Lewis V L Authors' objectives To review the efficacy (...) , Lewis V L. A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers. Dermatologic Surgery 1995; 21(2): 145-148 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Administration, Topical; Anti-Ulcer Agents /administration & Dermatologic Agents /administration & Growth Substances /administration & Humans; Pressure Ulcer /drug therapy; Randomized Controlled Trials as Topic; Skin, Artificial; dosage; dosage

1995 DARE.